Cspc Megalith Biopharmaceutical Co.,ltd.
Clinical trials sponsored by Cspc Megalith Biopharmaceutical Co.,ltd., explained in plain language.
-
New drug duo tested in battle against tough head and neck cancers
Disease control Recruiting nowThis study is testing whether a new combination of two drugs, SYS6010 and enlonstobart, can help control advanced head and neck cancer that has returned or spread. It will involve about 70 adults whose cancer is not suitable for surgery or standard radiation/chemotherapy. The mai…
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New cancer drug shows promise in early trials for Tough-to-Treat tumors
Disease control Recruiting nowThis early-stage trial is testing a new drug called SYS6043 in people with advanced solid tumors that have spread or returned after standard treatments. Researchers will first determine safe dosage levels, then expand to study how the drug behaves in the body and whether it helps…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for Tough-to-Treat lung cancer: experimental drug challenges standard chemo
Disease control Recruiting nowThis study is testing if a new drug called SYS6010 works better and is safer than standard platinum-based chemotherapy for people with advanced non-small cell lung cancer. It is for patients whose cancer has a specific genetic change (EGFR mutation) and has continued to grow desp…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC